A long-time member of a national health plan, Ms. Jones had been utilizing adalimumab biosimilar A for the past 18 months. It had been the preferred adalimumab product and thus is associated with the least out-of-pocket cost. On January 15, she opens her newly delivered medication, and finds a different biosimilar medication, with a different … Continue reading Avoiding Patient Disruption in Frequent Biosimilar Switching: A Focus on the Specialty Pharmacy